Your browser doesn't support javascript.
loading
Transition to lanadelumab-flyo from three medications for a hereditary angioedema patient with a variant in the SYTL2 gene: A case report.
Burns, Stephanie; Lewis, Elena.
Afiliação
  • Burns S; Western Michigan University Kalamazoo MI USA.
  • Lewis E; Asthma Allergy Centers Portage MI USA.
Clin Case Rep ; 9(4): 2438-2441, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33936709
ABSTRACT
Non-SERPING1 gene variant hereditary angioedema patients often need to take progesterone, attenuated androgens, and antifibrinolytics to control symptoms. These drugs may need to be tapered to extinction or reduced as lanadelumab-flyo reaches maximum concentration.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article